How were Apricus Biosciences' earnings last quarter?

Apricus Biosciences, Inc. (NASDAQ:APRI) announced its earnings results on Wednesday, October, 31st. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.02.

What other stocks do shareholders of Apricus Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Apricus Biosciences investors own include Scotts Miracle-Gro (SMG) , Pfizer (PFE) , Just Eat Takeaway.com (GRUB) , Boston Beer (SAM) , Palatin Technologies (PTN) , Synergy Pharmaceuticals (SGYP) , Amicus Therapeutics (FOLD) , Avon Products (AVP) , Chesapeake Energy (CHKAQ) and Novavax (NVAX) .

NASDAQ:APRI

Apricus Biosciences (APRI) Stock Price, News & Analysis

→ AI “wealth window” is closing soon! (From Paradigm Press) (Ad)

Free APRI Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $0.32
▼
$0.35
50-Day Range: N/A
52-Week Range: $0.18
▼
$3.34

Volume: 272,346 shs
Average Volume: 558,386 shs
Market Capitalization: $9.52 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Competitors Social Media

Get Apricus Biosciences alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Apricus Biosciences Stock (NASDAQ:APRI)

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system disorders. The firm's portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior in Major Depressive Disorder �or Post-Traumatic Stress Disorder, �amyotrophic lateral sclerosis, Sanfilippo syndrome, Parkinson's disease, other psychiatric and movement disorders plus orphan diseases. The company was founded by Raj Mehra in 2016 and is headquartered in New York, NY.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

APRI Stock News Headlines

May 16, 2023 | finance.yahoo.com

Lundquist Institute Start-Up Vitalex Biosciences Awarded Grant from NIAID/NIH

May 16, 2023 | marketwatch.com

Erectile Dysfunction Market Analysis and Growth Foresights till 2031

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 29, 2023 | marketwatch.com

Erectile Dysfunction Drugs Market Market Projection and Growth Drivers 2023-2028

March 11, 2023 | marketwatch.com

Erectile Dysfunction Drugs Market 2023-2028 Recent Study by Trend and Growth Analysis

January 10, 2023 | marketwatch.com

Erectile Dysfunction Medicine Market : Key Player, Competition Weakness and Strengths from 2023 to 2028

December 18, 2022 | marketwatch.com

Erectile Dysfunction Market Market Size 2023 Industry Analysis, Key Players, Regional Demand, Opportunity and Forecast 2028

October 15, 2022 | marketwatch.com

Erectile Dysfunction Market Size From 2022 To 2029 And Unlimited Opportunities for New Companies and Latest Developments

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

September 30, 2022 | finanznachrichten.de

Diurnal Group - Proposed acquisition by Neurocrine Biosciences

September 13, 2022 | markets.businessinsider.com

Great Psychedelics And Business Events Are Coming In Q4: Check Them Out Here

September 9, 2022 | markets.businessinsider.com

Seelos Therapeutics to Participate in the Guggenheim Nantucket Therapeutics Conference

August 24, 2022 | markets.businessinsider.com

Seelos Receives R&D Grant From Michael J. Fox Foundation For Parkinson's Research For SLS-004

August 16, 2022 | marketwatch.com

At 5.6% CAGR, Erectile Dysfunction Market Size Set to Register 7328.5 million USD by 2028

August 6, 2022 | marketwatch.com

Erectile Dysfunction Treatment Drugs Market 2022, Worth USD 7328.5 Mn by 2028 at CAGR of 5.6% – Report Spread across 85 Pages

June 29, 2022 | finanznachrichten.de

Aytu BioPharma, Inc.: Aytu BioPharma Announces the Appointment of Vivian Liu to the Company's Board of Directors

June 29, 2022 | apnews.com

Aytu BioPharma Announces the Appointment of Vivian Liu to the Company’s Board of Directors

March 12, 2022 | benzinga.com

Erectile Dysfunction Drugs Market Grow at a CAGR of 5.0% During 2017- 2027

December 20, 2021 | fool.com

Investing in Psychedelic Stocks

December 16, 2021 | markets.businessinsider.com

Seelos Therapeutics to Participate in the 11th Annual LifeSci Partners Corporate Access Event

November 24, 2021 | markets.businessinsider.com

Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma's Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine

November 10, 2021 | markets.businessinsider.com

Seelos Therapeutics to Present at the 4th Annual ALS ONE Research Symposium

October 26, 2021 | finance.yahoo.com

Apricus Biosciences to Present at the 2016 BIO Investor Forum

October 1, 2021 | markets.businessinsider.com

Seelos Therapeutics to Present a Poster on SLS-002 (Intranasal Racemic Ketamine) at the 2021 IASR/AFSP International Summit on Suicide Research

September 27, 2021 | markets.businessinsider.com

Why This Seelos Therapeutics Analyst Is Turning Bullish On Potential Trial Results

September 9, 2021 | markets.businessinsider.com

Seelos Therapeutics to Participate in Two Investor Conferences in September

September 1, 2021 | markets.businessinsider.com

Seelos Therapeutics Announces Senior Management Appointments

See More Headlines

Receive APRI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apricus Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 10/31/2018
Today: 4/18/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:APRI
CUSIP: N/A
CIK: 1017491
Web: www.apricusbio.com
Phone: (646) 293-2100
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.99)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $320,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -216.45%
Return on Assets: -153.13%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.86
Quick Ratio: 3.86

Sales & Book Value

Annual Sales: $5.76 million
Price / Sales: 1.62
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.29 per share
Price / Book: 1.14

Miscellaneous

Outstanding Shares: 28,170,000
Free Float: N/A
Market Cap: $9.35 million
Optionable: Not Optionable
Beta: 1.20

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Raj Mehra
Chairman, President, CEO & Chief Financial Officer
Jessica Kardish
Vice President-Clinical Development & Operations
Lucas Pilipski
Executive Director-Clinical Operations
Tim Whitaker
Chief Medical Officer
Gopal Krishna
Head-Manufacturing & Technical Operations

Key Competitors

View All Competitors

APRI Stock Analysis - Frequently Asked Questions

How were Apricus Biosciences' earnings last quarter?: Apricus Biosciences, Inc. (NASDAQ:APRI) announced its earnings results on Wednesday, October, 31st. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.02.
What other stocks do shareholders of Apricus Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Apricus Biosciences investors own include Scotts Miracle-Gro (SMG), Pfizer (PFE), Just Eat Takeaway.com (GRUB), Boston Beer (SAM), Palatin Technologies (PTN), Synergy Pharmaceuticals (SGYP), Amicus Therapeutics (FOLD), Avon Products (AVP), Chesapeake Energy (CHKAQ) and Novavax (NVAX).

This page (NASDAQ:APRI) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Apricus Biosciences (APRI) Stock Price, News & Analysis

About Apricus Biosciences Stock (NASDAQ:APRI)

APRI Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

APRI Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info